Signing of a Large Contract With an Industry Leader for Kalray's DPU Processor
14.11.2022 11:00:00 EET | Business Wire | Press release
Kalray (Euronext Growth Paris: ALKAL), a leading provider of hardware and software technologies and solutions for high-performance, data centric computing markets, from cloud to edge, announces that it has signed a major contract with a world leader in the field of high technology, listed on the NASDAQ, in accordance with the negotiations announced recently1.
Éric Baissus, Kalray CEO, says : “ The signing of this contract is a major milestone for Kalray. It is the result of nearly 18 months of in-depth evaluation by our customer of our technology, which has demonstrated its relevance compared to the most advanced alternatives in the industry, the quality of our teams, whom I would like to thank for the remarkable work that was done throughout these discussions, and of our ability, as a strategic partner company to offer the guarantees required to sign a contract of this magnitude with a major international player. This contract is further proof of the change of dimension initiated by our company and a further step towards becoming one of the world leaders in our market. ”
A MAJOR CONTRACT, WHICH CONFIRMS KALRAY'S ABILITY TO CONVINCE MARKET LEADERS
This major contract was signed with an American company listed on the NASDAQ, a major player in the industry that generated several tens of billions of dollars in revenue in 2021 and had a market capitalization of over one hundred billion dollars.
The contract covers the development and supply of acceleration cards based on Kalray's DPU processors, on which the customer intends to build the next generation of its products and services. This agreement includes technical, commercial and financial terms and represents a commercial potential of several tens of millions of Euros per year. The signing of this contract demonstrates Kalray's ability to win over the most demanding players in the market and to sign contracts with very high revenue-generating potential.
AND CONFIRMS THE RELEVANCE OF KALRAY'S TECHNOLOGY AND BUSINESS MODEL
The key criterion in the customer's choice was the ability of Kalray's technology and its offering of acceleration cards to process the customer's data with the best performance/price and performance/consumption ratio. The advanced tests showed that Kalray's solution was a factor of 3 to 5 times better than the competition, representing a potential savings for the customer of several hundred million dollars over the life of the project. In addition to this cost/performance advantage, Kalray's solutions can be easily programmed and can handle a wide variety of data processing in parallel, which traditional alternatives such as GPUs or FPGAs do not allow.
Kalray's ability to support such a large contract comes from its "fabless" business model. Like other high-growth companies like NVIDIA, Kalray does not have a factory. Instead, Kalray relies on industry partners such as TSMC, the world's largest semiconductor manufacturer, and Wistron, one of the world's largest card and server manufacturers, to manufacture its hardware solutions without having to invest in a production facility.
A CONTRACT IN 3 CLEARLY DEFINED STAGES
The first phase began with the signing of the contract and covers the manufacturing of an ultra-high performance accelerator card including 4 Kalray MPPA® DPU processors and the support of the customer's development teams for the development of their next generation product. The customer has already committed $1 million to Kalray to cover the various phases of this milestone, which is expected to be completed in the second half of 2023.
The second step will be for the customer, once performance is confirmed, to launch pre-series production of its new generation of product, resulting in initial multi-million Euro card orders.
The third step will be volume production, which should represent orders of several thousand cards per year, i.e. revenues of several tens of millions of Euros per year, over a period of at least 5 years, which should be starting in 2025.
This signature is in line with Kalray's strategy to work with major players looking for a unique technology for very large projects. The company is currently in discussions with several players with the same profile and believes that this first major contract should be a catalyst for signing new contracts with this type of first tier customer and with all its prospects in general.
ABOUT KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data centric computing markets, from cloud to edge.
Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures. Its offers include its unique patented DPU (Data Processing Unit) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Sciences, Scientific Research, Edge Computing, Automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
________________________
1 See press release dated from September 21, 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005083/en/
Contact information
INVESTORS
Eric BAISSUS
contactinvestisseurs@kalrayinc.com
+33 4 76 18 90 71
ACTUS Finance & Communication
Anne-Pauline PETUREAUX
kalray@actus.fr
+33 1 53 67 36 72
PRESS
Sylvie DAM
communication@kalrayinc.com
+33 4 76 18 90 71
ACTUS Finance & Communication
Serena BONI
sboni@actus.fr
+33 4 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 15:00:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, umbilical, manifolds, multiphase flowmeters and control systems, along with installation, commissionin
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 13:00:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The net proceeds of this financing are expected to support Agenus’ strategic prioritization of botensilimab and balstilimab (BOT+BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including advancement of ROBBIN1, the Company’s planned registrational Phase 3 neoadjuvant trial in microsatellite-stable (MSS) colon cancer. High-risk Stage II and Stage III MSS colon cancer affect an estimated 38,000 patients annually in the US and more than 200,000 patients worldwide,2 representing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
